TY - JOUR
T1 - Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival
AU - Yamamoto, Takaya
AU - Niibe, Yuzuru
AU - Aoki, Masahiko
AU - Shintani, Takashi
AU - Yamada, Kazunari
AU - Kobayashi, Mitsuru
AU - Yamashita, Hideomi
AU - Ozaki, Masatoki
AU - Manabe, Yoshihiko
AU - Onishi, Hiroshi
AU - Yahara, Katsuya
AU - Nishikawa, Atsushi
AU - Katsui, Kuniaki
AU - Oh, Ryoong Jin
AU - Terahara, Atsuro
AU - Jingu, Keiichi
N1 - Funding Information:
This study was supported by a Grant-in-aid for research on radiation oncology of JASTRO 2015–2016 which was provided by public corporation “Koueki Shadan Hojin Nihon Houshasenn Shuyou Gakkai” in Japanese. This funding was used to collect to the data from each institutions. Acknowledgements
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Background: Successful local therapy for oligometastases may lead to longer survival. The purpose of this multicentre retrospective study was to investigate factors affecting the local control (LC) of pulmonary oligometastases treated by stereotactic body radiotherapy (SBRT) and to investigate the impact of LC on survival. Methods: The inclusion criteria included 1 to 5 metastases, the primary lesion and other extrathoracic metastases were controlled before SBRT, and the biological effective dose (BED10) of the SBRT was 75 Gy or more. The Cox proportional hazards model was used for analyses. Results: Data of 1378 patients with 1547 tumours from 68 institutions were analysed. The median follow-up period was 24.2 months. The one-year, 3-year and 5-year LC rates were 92.1, 81.3 and 78.6%, respectively, and the 1-year, 3-year and 5-year overall survival rates were 90.1, 60.3 and 45.5%, respectively. Multivariate analysis for LC showed that increased maximum tumour diameter (p = 0.011), type A dose calculation algorithm (p = 0.005), shorter overall treatment time of SBRT (p = 0.035) and colorectal primary origin (p < 0.001 excluding oesophagus origin) were significantly associated with a lower LC rate. In the survival analysis, local failure (p < 0.001), worse performance status (1 vs. 0, p = 0.013; 2–3 vs. 0, p < 0.001), oesophageal primary origin (vs. colorectal origin, p = 0.038), squamous cell carcinoma (vs. adenocarcinoma, p = 0.006) and increased maximum tumour diameter (p < 0.001) showed significant relationships with shorter survival. Conclusions: Several factors of oligometastases and SBRT affected LC. LC of pulmonary oligometastases by SBRT showed a significant survival benefit compared to patients with local failure.
AB - Background: Successful local therapy for oligometastases may lead to longer survival. The purpose of this multicentre retrospective study was to investigate factors affecting the local control (LC) of pulmonary oligometastases treated by stereotactic body radiotherapy (SBRT) and to investigate the impact of LC on survival. Methods: The inclusion criteria included 1 to 5 metastases, the primary lesion and other extrathoracic metastases were controlled before SBRT, and the biological effective dose (BED10) of the SBRT was 75 Gy or more. The Cox proportional hazards model was used for analyses. Results: Data of 1378 patients with 1547 tumours from 68 institutions were analysed. The median follow-up period was 24.2 months. The one-year, 3-year and 5-year LC rates were 92.1, 81.3 and 78.6%, respectively, and the 1-year, 3-year and 5-year overall survival rates were 90.1, 60.3 and 45.5%, respectively. Multivariate analysis for LC showed that increased maximum tumour diameter (p = 0.011), type A dose calculation algorithm (p = 0.005), shorter overall treatment time of SBRT (p = 0.035) and colorectal primary origin (p < 0.001 excluding oesophagus origin) were significantly associated with a lower LC rate. In the survival analysis, local failure (p < 0.001), worse performance status (1 vs. 0, p = 0.013; 2–3 vs. 0, p < 0.001), oesophageal primary origin (vs. colorectal origin, p = 0.038), squamous cell carcinoma (vs. adenocarcinoma, p = 0.006) and increased maximum tumour diameter (p < 0.001) showed significant relationships with shorter survival. Conclusions: Several factors of oligometastases and SBRT affected LC. LC of pulmonary oligometastases by SBRT showed a significant survival benefit compared to patients with local failure.
KW - Local control
KW - Metastasis-directed therapy
KW - Oligo-recurrence
KW - Pulmonary oligometastases
KW - Stereotactic body radiotherapy
KW - Sync-oligometastases
UR - http://www.scopus.com/inward/record.url?scp=85092629969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092629969&partnerID=8YFLogxK
U2 - 10.1186/s12885-020-07514-9
DO - 10.1186/s12885-020-07514-9
M3 - Article
C2 - 33054721
AN - SCOPUS:85092629969
VL - 20
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
IS - 1
M1 - 997
ER -